EWM
RCKT icon

Evermay Wealth Management’s Rocket Pharmaceuticals RCKT Stock Holding History

Evermay Wealth Management’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-25
Closed -$539 – 623
2024
Q2 		$539 Hold
25
– – ﹤0.01% 576
2024
Q1 		$674 Buy
+25
New +$710 ﹤0.01% 572

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Evermay Wealth Management's RCKT Position: Q3 2024 in Review

Evermay Wealth Management sold out of Rocket Pharmaceuticals (RCKT) in Q3 2024, closing a stake of 25 shares — an estimated $539 sold.

Evermay Wealth Management first reported a position in RCKT in Q1 2024 and held it in 2 quarters. The position peaked at $674 in Q1 2024. 191 funds tracked by Wall St. Rank hold RCKT as of Q3 2024.

  • Evermay Wealth Management reported no remaining Rocket Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Evermay Wealth Management sold 25 Rocket Pharmaceuticals shares in Q3 2024, an estimated $539.
  • Evermay Wealth Management first reported a position in Rocket Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Evermay Wealth Management's Rocket Pharmaceuticals position peaked at $674 in Q1 2024.
  • 191 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2024.

Based on Evermay Wealth Management's 13F filing for Q3 2024, filed 25 Oct 2024.